Cleveland Biolabs
Cleveland BioLabs, Inc. is a biopharmaceutical company focused on developing innovative treatments that activate the immune system to address critical medical needs, particularly in oncology and radiation protection. Founded in 2003 and headquartered in Buffalo, New York, the company utilizes a proprietary platform of toll-like immune receptor activators to create therapies aimed at mitigating radiation injuries and enhancing cancer treatments. Its lead product candidate, entolimod, is an immune-stimulatory agent designed to serve as a medical countermeasure for acute radiation syndrome and to treat various cancer-related conditions. Additionally, Cleveland BioLabs is working on Mobilan, a recombinant adenovirus aimed at enhancing immune response. The company collaborates with renowned institutions such as the Cleveland Clinic and Roswell Park Cancer Institute to advance its research and development efforts.
Cytocom, Inc. a specialty biotech company, founded by patients, specializing in repurposing of drugs that deploys their patented therapies focused on the activation and rebalancing of the body’s immune system. Stimulating the body’s immune system remains one of the most promising approaches in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory conditions and other chronic infectious diseases.
Panacela Labs, Inc. is a joint venture established in 2011, primarily focused on developing gene therapy drugs for cancer and infectious diseases. The company is a collaboration between Cleveland BioLabs, a clinical-stage biotechnology firm, and RUSNANO, a major Russian investment entity, along with key partnerships with renowned institutions such as Roswell Park Cancer Institute, Children’s Cancer Institute of Australia, and Cleveland Clinic Foundation. With a majority ownership of 54.6% held by Cleveland BioLabs, Panacela Labs operates from the Innovation Center "Skolkovo." The company's therapeutic innovations aim to enhance cancer immunotherapy, improve chemotherapy efficacy, and provide targeted treatments for prostate cancer and other conditions, ultimately striving to improve patient outcomes and quality of life.
Panacela Labs, Inc. is a joint venture established in 2011, primarily focused on developing gene therapy drugs for cancer and infectious diseases. The company is a collaboration between Cleveland BioLabs, a clinical-stage biotechnology firm, and RUSNANO, a major Russian investment entity, along with key partnerships with renowned institutions such as Roswell Park Cancer Institute, Children’s Cancer Institute of Australia, and Cleveland Clinic Foundation. With a majority ownership of 54.6% held by Cleveland BioLabs, Panacela Labs operates from the Innovation Center "Skolkovo." The company's therapeutic innovations aim to enhance cancer immunotherapy, improve chemotherapy efficacy, and provide targeted treatments for prostate cancer and other conditions, ultimately striving to improve patient outcomes and quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.